Joseph P. Lyssikatos
CHIEF SCIENTIFIC OFFICER · Enliven Therapeutics, Inc.
- 2024
- Feb 18, 2026
- 15
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Joseph P. Lyssikatos files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
- Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
- Helen Louise Collins - $5.39M in ELVN purchases and sales in the last 12 months
- Benjamin Hohl - $1.53M in ELVN purchases and sales in the last 12 months
- Anish Patel - $1.47M in ELVN purchases and sales in the last 12 months
- Lori Anne Kunkel - $850K in ELVN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Joseph P. Lyssikatos?
Joseph P. Lyssikatos is a corporate insider, tracked as CHIEF SCIENTIFIC OFFICER of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Joseph P. Lyssikatos last file a Form 4?
The most recent primary Form 4 on record is dated 18 February 2026, one of 15 filings going back to 2024.
Has Joseph P. Lyssikatos been buying or selling stock?
Recorded transactions: 0 open-market purchases and 26 open-market sales ($7.24M) across all tracked filings.
